PL370850A1 - Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli - Google Patents

Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli

Info

Publication number
PL370850A1
PL370850A1 PL370850A PL37085004A PL370850A1 PL 370850 A1 PL370850 A1 PL 370850A1 PL 370850 A PL370850 A PL 370850A PL 37085004 A PL37085004 A PL 37085004A PL 370850 A1 PL370850 A1 PL 370850A1
Authority
PL
Poland
Prior art keywords
phenyl
propylsulphanylmethyl
pharmaceuticall
tertbutylamine
chloroquinoline
Prior art date
Application number
PL370850A
Other languages
English (en)
Other versions
PL205637B1 (pl
Inventor
Osman Achmatowicz
Krzysztof Wiśniewski
Jan Ramza
Wiesław Szelejewski
Barbara Szechner
Original Assignee
Instytut Farmaceutyczny
Zakłady Farmaceutyczne POLPHARMA S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Farmaceutyczny, Zakłady Farmaceutyczne POLPHARMA S.A. filed Critical Instytut Farmaceutyczny
Priority to PL370850A priority Critical patent/PL205637B1/pl
Priority to US11/577,721 priority patent/US20090005413A1/en
Priority to EP05799649A priority patent/EP1853563A1/en
Priority to PCT/PL2005/000067 priority patent/WO2006043846A1/en
Publication of PL370850A1 publication Critical patent/PL370850A1/pl
Publication of PL205637B1 publication Critical patent/PL205637B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL370850A 2004-10-22 2004-10-22 Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli PL205637B1 (pl)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL370850A PL205637B1 (pl) 2004-10-22 2004-10-22 Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
US11/577,721 US20090005413A1 (en) 2004-10-22 2005-10-21 Novel Salt of Montelukast
EP05799649A EP1853563A1 (en) 2004-10-22 2005-10-21 Salt of montelukast with tert.-butylamine
PCT/PL2005/000067 WO2006043846A1 (en) 2004-10-22 2005-10-21 Salt of montelukast with tert.-butylamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL370850A PL205637B1 (pl) 2004-10-22 2004-10-22 Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli

Publications (2)

Publication Number Publication Date
PL370850A1 true PL370850A1 (pl) 2006-05-02
PL205637B1 PL205637B1 (pl) 2010-05-31

Family

ID=35929721

Family Applications (1)

Application Number Title Priority Date Filing Date
PL370850A PL205637B1 (pl) 2004-10-22 2004-10-22 Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli

Country Status (4)

Country Link
US (1) US20090005413A1 (pl)
EP (1) EP1853563A1 (pl)
PL (1) PL205637B1 (pl)
WO (1) WO2006043846A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136693A2 (en) 2007-05-02 2008-11-13 Zaklady Farmaceutyczne Polpharma Sa Process for the preparation of sodium salt of l-(((l(r)-(3-(2-(7-chloro-2- quinolinyl)-ethenyl)phenyl)-3-(2-(l-hydroxy-l- methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563776A1 (en) 2004-04-21 2005-11-10 Teva Pharmaceutical Industries Ltd. Processes for preparing montelukast sodium
US7812168B2 (en) 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
EP2069307A4 (en) * 2006-08-04 2010-03-03 Matrix Lab Ltd PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS
EP1886998A1 (en) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Purification process of montelukast and its amine salts
WO2008126075A1 (en) * 2007-04-12 2008-10-23 Chemagis Ltd. Process for preparing montelukast and salts thereof using optically impure 2-(2-(3(s)-(3-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-hydroxypropyl)phenyl-2-propanol
CZ302518B6 (cs) * 2007-07-09 2011-06-29 Zentiva, A. S. Zpusob izolace a cištení montelukastu
WO2009027990A1 (en) * 2007-08-29 2009-03-05 Morepen Laboratories Limited Salts of montelukast and process therefor
EP2053043A1 (en) 2007-10-26 2009-04-29 Inke, S.A. Crystalline salt of montelukast
KR100920314B1 (ko) * 2007-11-20 2009-10-08 보령제약 주식회사 몬테루카스트 신규한 염 및 그의 제조방법
CZ2008167A3 (cs) * 2008-03-14 2010-02-24 Zentiva, A. S. Specifické necistoty montelukastu
KR101123292B1 (ko) * 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2011004298A1 (en) 2009-07-09 2011-01-13 Alembic Limited Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
WO2011072383A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
EP2552892A1 (en) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
CN105585524B (zh) * 2016-02-29 2018-03-02 山东新时代药业有限公司 一种由孟鲁司特酸制备孟鲁司特钠的方法
CN105924392B (zh) * 2016-02-29 2018-03-02 山东新时代药业有限公司 一种孟鲁司特钠制备方法
CN113521044B (zh) * 2021-06-04 2022-09-16 中国人民解放军南部战区总医院 2-(1-(巯基甲基)环丙基)乙酸在作为和/或制备β-内酰胺酶抑制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454069A (en) 1979-08-24 1984-06-12 Beecham Group Limited Clavulanic acid salts and their preparation from the tertiary butyl amine salt
IE912115A1 (en) * 1990-06-25 1992-01-01 Takeda Chemical Industries Ltd Bisphosphonic acid derivatives, their production and use
HU222344B1 (hu) * 1990-10-12 2003-06-28 Merck Frosst Canada & Co. Eljárás telítetlen hidroxi-alkil-kinolinsavak, és ezeket tartalmazó gyógyszerkészítmények előállítására
TW416948B (en) * 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
EP1709001A2 (en) * 2004-01-28 2006-10-11 Pliva Istrazivanje i Razvoj d.o.o. Solid forms of montelukast acid
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136693A2 (en) 2007-05-02 2008-11-13 Zaklady Farmaceutyczne Polpharma Sa Process for the preparation of sodium salt of l-(((l(r)-(3-(2-(7-chloro-2- quinolinyl)-ethenyl)phenyl)-3-(2-(l-hydroxy-l- methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid

Also Published As

Publication number Publication date
US20090005413A1 (en) 2009-01-01
PL205637B1 (pl) 2010-05-31
WO2006043846A1 (en) 2006-04-27
WO2006043846B1 (en) 2006-07-06
EP1853563A1 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
PL370850A1 (pl) Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
HRP20170634T1 (hr) Kristalni oblici od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
EG25197A (en) Process for the manufacture of 1,2-dichloroethane
EG25196A (en) Process for the manufacture of 1,2-Dichloroethane
EP2308978B8 (en) Luciferase biosensor
ZA200703443B (en) Carbonyl compounds usable as coagulation factor Xa Inhibitors
TWI365179B (en) Process for the manufacture of 1,2-dichloroethane
EP1736711A4 (en) HUMIDITY CONTROL
EP1771441B8 (de) Neue carbonsäureamide als faktor xa-inhibitoren
AU2003278392A1 (en) 5- (substituted phenyl) -thiadiazolidine-3-ones and their use as ptp1b
ZA200606315B (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
EP1694118A4 (en) TISSUE PRESERVATION MEDIA
ZA200804241B (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quina-zolin-3-yl)-phenyl]-5-chlorothiophen-2-yl-sulfonylureas and forms and methods related thereto
IL178899A0 (en) [3.2.0] heterocyclic compounds and methods of using the same
ATE485279T1 (de) Verbessertes verfahren zur herstellung der salze von 4-(benzimidazolylmethylamin)-benzamiden
GB2399418B (en) Determination of virgin formation temperature
WO2006070023A3 (en) Method for reversing multiple resistance in animal cells
DE602005025450D1 (de) Homokinetisches gelenk
DE602004000558D1 (de) Mattierende Polymerzusammensetzung
IL179346A0 (en) 3-(4-(2-dihydroisoxazol-3-ylpyridin-5-yl)phenyl)-5-triazol-1-ylmethyloxazolidin-2-one derivatives as mao inhibitors for the treatment of bacterial infections
TWI347947B (en) Process for preparing [4-(1,3,4-oxadiazol-2-yl)phenyl] boronic acid and use thereof
ATE356120T1 (de) 2-phenyl-benzofuran-derivate, verfahren zur ihrer herstellung und ihre verwendung
GB2433504B (en) Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof
DE502004005704D1 (de) Dispersionen
AU2004906205A0 (en) Computerised Running Records Assistant Program